Herbert S. B. Baraf

2.8k total citations · 2 hit papers
45 papers, 1.9k citations indexed

About

Herbert S. B. Baraf is a scholar working on Rheumatology, Nephrology and Pharmacology. According to data from OpenAlex, Herbert S. B. Baraf has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 22 papers in Nephrology and 13 papers in Pharmacology. Recurrent topics in Herbert S. B. Baraf's work include Gout, Hyperuricemia, Uric Acid (22 papers), Inflammatory mediators and NSAID effects (11 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Herbert S. B. Baraf is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (22 papers), Inflammatory mediators and NSAID effects (11 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Herbert S. B. Baraf collaborates with scholars based in United States, Sweden and Japan. Herbert S. B. Baraf's co-authors include John S. Sundy, Michael A. Becker, Robert A. Yood, Allan N. Maroli, Royce W. Waltrip, William J. Huang, Sergio Gutiérrez‐Ureña, Edward L. Treadwell, Peter E. Lipsky and Faith D. Ottery and has published in prestigious journals such as JAMA, Journal of the American Society of Nephrology and American Journal of Obstetrics and Gynecology.

In The Last Decade

Herbert S. B. Baraf

44 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

2011 380 citations John S. Sundy, Herbert S. B. Baraf et al. profile →
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

2021 163 citations Bernard Combe, Alan Kivitz et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Herbert S. B. Baraf

Since Specialization

Citations

This map shows the geographic impact of Herbert S. B. Baraf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert S. B. Baraf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert S. B. Baraf more than expected).

Fields of papers citing papers by Herbert S. B. Baraf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert S. B. Baraf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert S. B. Baraf. The network helps show where Herbert S. B. Baraf may publish in the future.

Co-authorship network of co-authors of Herbert S. B. Baraf

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert S. B. Baraf. A scholar is included among the top collaborators of Herbert S. B. Baraf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert S. B. Baraf. Herbert S. B. Baraf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P084 Gout symptom improvements and patient outcomes with SEL-212 in gout refractory to conventional therapy: DISSOLVE I & II phase 3, double-blind, placebo-controlled clinical trials 2024 ·Lara D. Veeken ·Herbert S. B. Baraf, Puja Khanna, Anand Patel, (unknown), (unknown), Wesley DeHaan, (unknown), Peter G. Traber, Alan Kivitz	1
2	POS0033 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND OTHER SECONDARY CLINICAL OUTCOMES IN ADULTS WITH GOUT REFRACTORY TO CONVENTIONAL THERAPY TREATED WITH SEL-212: POOLED 6-MONTH DATA FROM THE PHASE 3 DISSOLVE I & II CLINICAL TRIALS 2024 ·Annals of the Rheumatic Diseases ·Puja Khanna, Amit Patel, (unknown), (unknown), (unknown), (unknown), Nana Kragh, (unknown), Wesley DeHaan, Peter G. Traber, Herbert S. B. Baraf	1
3	Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study 2023 ·Rheumatology and Therapy ·Alan Kivitz, Alvin F. Wells, (unknown), Herbert S. B. Baraf, Maureen Rischmueller, (unknown), Nasser Khan, Yihan Li, (unknown), Alan Friedman, Patrick Durez	3
4	LB0002 SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES 2023 ·Annals of the Rheumatic Diseases ·Herbert S. B. Baraf, Alan Kivitz, (unknown), Sheldon S. Leung, Onikepe Folarin, (unknown), (unknown), (unknown), Amit Patel, Wesley DeHaan, (unknown), Peter G. Traber	3
5	The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout 2023 ·Lara D. Veeken ·Herbert S. B. Baraf, Puja Khanna, Alan Kivitz, Vibeke Strand, Hyon K. Choi, Robert Terkeltaub, Nicola Dalbeth, Wesley DeHaan, (unknown), Peter G. Traber, Robert T. Keenan	16
6	Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response 2022 ·Current Rheumatology Reports ·(unknown), Herbert S. B. Baraf, Robert T. Keenan, (unknown), (unknown), (unknown), Christianne Yung, (unknown), (unknown), Abdul Abdellatif, (unknown), N. Lawrence Edwards, Vibeke Strand	8
7	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial breakdown → 2021 ·Annals of the Rheumatic Diseases ·Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J. Simón, Herbert S. B. Baraf, Uma Kumar, F. Matzkies, Beatrix Bartók, Lei Ye, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Mark C. Genovese, Neelufar Mozaffarian, Robert Landewé, Sang‐Cheol Bae, (unknown), Peter Nash	163
8	Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase 2019 ·Rheumatology and Therapy ·Robert T. Keenan, Herbert S. B. Baraf, Brian LaMoreaux	19
9	The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients 2018 ·Drugs in R&D ·(unknown), (unknown), Herbert S. B. Baraf, Shawn C. Black, (unknown), Joseph Tkacz, (unknown), Raphael J. DeHoratius	4
10	Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy 2014 ·JCR Journal of Clinical Rheumatology ·Herbert S. B. Baraf, Robert A. Yood, Faith D. Ottery, John S. Sundy, Michael A. Becker	42
11	A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee 2012 ·Osteoarthritis and Cartilage ·Vibeke Strand, Herbert S. B. Baraf, P T Lavin, Sang Yup Lim, Hiroyuki Hosokawa	89
12	Tolerability of Topical Diclofenac Sodium 1% Gel for Osteoarthritis in Seniors and Patients With Comorbidities 2012 ·The American journal of geriatric pharmacotherapy ·Herbert S. B. Baraf, Morris S. Gold, Richard A. Petruschke, (unknown)	25
13	Long-term safety of pegloticase in chronic gout refractory to conventional treatment 2012 ·Annals of the Rheumatic Diseases ·Michael A. Becker, Herbert S. B. Baraf, Robert A. Yood, (unknown), Janitzia Vázquez‐Mellado, Faith D. Ottery, Dinesh Khanna, John S. Sundy	83
14	Safety and Efficacy of Topical Diclofenac Sodium Gel for Knee Osteoarthritis in Elderly and Younger Patients 2010 ·Drugs & Aging ·Herbert S. B. Baraf, F. Michael Gloth, H. Richard Barthel, Morris S. Gold, Roy D. Altman	51
15	Safety and Efficacy of Topical Diclofenac Sodium 1% Gel in Knee Osteoarthritis: A Randomized Controlled Trial 2010 ·The Physician and Sportsmedicine ·Herbert S. B. Baraf, Morris S. Gold, Michael B. Clark, Roy D. Altman	42
16	Resolution of gouty tophi after twelve weeks of pegloticase treatment 2008 ·Arthritis & Rheumatism ·Herbert S. B. Baraf, Alan K. Matsumoto, Allan N. Maroli, Royce W. Waltrip	37
17	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol–conjugated uricase) in patients with treatment‐failure gout: Results of a phase II randomized study 2008 ·Arthritis & Rheumatism ·John S. Sundy, Michael A. Becker, Herbert S. B. Baraf, André Barkhuizen, Larry W. Moreland, William J. Huang, Royce W. Waltrip, Allan N. Maroli, (unknown), (unknown)	129
18	Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty‐two–week, randomized, controlled study 2005 ·Arthritis & Rheumatism ·Désirée van der Heijde, Herbert S. B. Baraf, César Ramos-Remus, Andrei Călin, Arthur L. Weaver, Michael Schiff, Margaret K. James, (unknown), Alise Reicin, Agustin Melian, Maxime Dougados	156
19	Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial 2004 ·Journal of the American Geriatrics Society ·Alan Kivitz, Maria Greenwald, Stanley Cohen, Adam B. Polis, (unknown), Mary Dixon, (unknown), (unknown), Herbert S. B. Baraf, Richard A. Petruschke, Alan K. Matsumoto, Gregory P. Geba, (unknown), (unknown)	27
20	Circulating Intercellular Adhesion Molecule-1 in Patients with Systemic Sclerosis 1993 ·Clinical Immunology and Immunopathology ·Petros P. Sfikakis, (unknown), Herbert S. B. Baraf, Robert Lipnick, Gary L. Klipple, George C. Tsokos	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact